AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MH

Go back to AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
AbbVie (NYSE: ABBV) Delayed: 227.73 +2.96 (1.32%)
Previous Close $224.77    52 Week High $68.12 
Open $227.50    52 Week Low $50.71 
Day High $228.40    P/E 49.40 
Day Low $224.32    EPS $4.61 
Volume 4,086,391